ClinicalTrials.gg
Active, not recruitingNCT06747572Updated Nov 12, 2026

Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease

An observational study in Autosomal Dominant Polycystic Kidney Disease (ADPKD), sponsored by Vertex Pharmaceuticals Incorporated. Active, not recruiting at 45 sites in 9 countries. Open to participants aged 12 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Vertex Pharmaceuticals Incorporated · Observational

Updated Nov 12, 20262 sites added2 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
401
Ages
12 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 85 studies in Polycystic Kidney, Autosomal Dominant with a site in United States — 14 open to participants now, 25 under way, 1 of them phase 3. Polycystic Kidney, Autosomal Dominant · United States.

Enrollment
4th of 22
401 · median 90
Started
2024
with 2 others
Observational
22 of 85
6 open now
Primary completion
2026-12
later than 3 of 24 live
Registered
73rd of 85
by date
Lead sponsor
6 of 85
Vertex Pharmaceuticals Incorporated

Among the 85 studies in Polycystic Kidney, Autosomal Dominant with a site in United States, this one is the 4th largest by enrollment of the 22 observational ones that give a count, is one of 3 that started in 2024, is one of 22 observational ones, reaches primary completion later than 3 of the 24 other live ones, and was the 73rd registered.

Polycystic Kidney, Autosomal Dominant

185 studies on the registry are indexed under Polycystic Kidney, Autosomal Dominant; 42 are open to participants now.

Browse Polycystic Kidney, Autosomal Dominant studies →

Open to participants now

14 of the 85 studies in Polycystic Kidney, Autosomal Dominant with a site in United States are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 30 Polycystic Kidney, Autosomal Dominant studies recruiting now, 8 (27%) set no upper age limit and 19 (63%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 12 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 85 studies in Polycystic Kidney, Autosomal Dominant with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to estimate the prevalence, demographic, and clinical characteristics of PKD1/2 gene variant groups in the ADPKD population.

03

Conditions studied

  • Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Keywords

  • ADPKD
04

Who can participate

Ages eligible
12 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Part A: Male and female participants aged 12 to 65 years old, inclusive, diagnosed with ADPKD who have not reached end stage kidney disease (ESKD). Part B: Male and female participants aged 12 to 65 years old, inclusive, who have completed Part A and who have genotyping results confirming an eligible non-truncating variant in PKD1 and who are at risk for rapidly progressive disease, based upon historical total kidney volume (TKV) or kidney length.

Eligibility criteria

Key Inclusion Criteria:

  • Estimated (eGFR) greater than or equal to (≥) 30 milliliter per minute (mL/min)/1.73 m\^2
  • Willing and able to comply with scheduled visits and other study procedures
  • A pre-existing diagnosis of ADPKD as defined in the protocol

Key Exclusion Criteria:

  • History of kidney disease other than ADPKD that in the opinion of the investigator would independently impact the natural history of ADPKD
  • History of solid organ or bone marrow transplantation or nephrectomy
  • Ongoing renal replacement therapy or planning to start renal replacement therapy less than or equal to (≤)12 months from the Genotyping Visit in Part A

Other protocol defined Inclusion/Exclusion criteria will apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
401 participants (actual)
Patient registry
No

Groups and cohorts

  • Part A

    Eligible participants will complete a single visit to complete a blood sample collection for PKD1/2 genotyping.

  • Part B

    Participants who have completed all assessments in Part A and have a subset of variants in PKD1 will complete 1 year of follow-up.

06

What researchers measure

Primary outcomes

  1. Part A: Percentage of PKD1 Gene Variant Groups in the ADPKD Population

    Time frame: Genotyping Visit on Day 1 of Part A (Part A duration: 1 Calendar Day)

  2. Part A: Weight of Participants Within Each PKD1 Gene Variant Group

    Time frame: Genotyping Visit on Day 1 of Part A (Part A duration: 1 Calendar Day)

  3. Part A: Height of Participants Within Each PKD1 Gene Variant Group

    Time frame: Genotyping Visit on Day 1 of Part A (Part A duration: 1 Calendar Day)

  4. Part A: Body Mass Index (BMI) of Participants Within Each PKD1 Gene Variant Group

    Time frame: Genotyping Visit on Day 1 of Part A (Part A duration: 1 Calendar Day)

  5. Part A: Age of Participants at ADPKD Diagnosis Within Each PKD1 Gene Variant Group

    Time frame: Genotyping Visit on Day 1 of Part A (Part A duration: 1 Calendar Day)

07

Study locations

45 sites
08

References and documents

Individual participant data

Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/our-science/clinical-trials-data-sharing/

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2024 (actual). Primary completion is estimated for Dec 2026, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2024
First posted
Dec 24, 2024
StartActual
Dec 19, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 2 sites removed
Show 2 added (2 United States)
  • Clinical & Translational Science Unit (CTSU) - Nephrology · Kansas City, United States
  • University of Maryland Medical Center - General Clinical Research Center · Baltimore, United States
Show 2 removed
  • University of Kansas Medical Center · Kansas City, United States
  • General Clinical Research Center, University of Maryland Baltimore · Baltimore, United States
across 2 updates, Oct 26, 2026 – Nov 12, 2026
Show all 2 updates
  1. Nov 12, 2026
    1 site added, 1 site removed
    Show site
    • University of Maryland Medical Center - General Clinical Research Center · Baltimore, United States
    Show 1 removed
    • General Clinical Research Center, University of Maryland Baltimore · Baltimore, United States
    + 1 other change: verification date
  2. Oct 26, 2026
    1 site added, 1 site removed
    Show site
    • Clinical & Translational Science Unit (CTSU) - Nephrology · Kansas City, United States
    Show 1 removed
    • University of Kansas Medical Center · Kansas City, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06747572
Responsible party
Sponsor
First posted
Dec 24, 2024
Start date
Dec 19, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Nov 12, 2026
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion